Drugs / JNJ-42396302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01732237 | Aug → Oct 2012 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-42396302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01732237 ↗ |
| Modality | Small molecule | — CHEMBL2180408 ↗ |
| Route | Oral | “will be administered orally” NCT01732237 ↗ |